Paradigm Biocapital Advisors LP
- SEC CIK
- 0001855655
- Latest filing
- Aug 14, 2026
VRDN holding history
Viridian Therapeutics, Inc. in every 13F filed by Paradigm Biocapital Advisors LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
VRDN overviewAll 13F holders of VRDNFull Q2 2026 holdings
- Shares (Q2 2026)
- 6,723,788
- Value
- $123.5M
- % of portfolio
- 2.3%
- Quarters held
- 19
- Since Q4 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 6,723,788 | $123.5M | 2.3% | +3,574,895+113.5% | Added | Holders |
| Q1 2026 | 3,148,893 | $61.6M | 1.3% | +1,705,791+118.2% | Added | Holders |
| Q4 2025 | 1,443,102 | $44.9M | 1.2% | −1,166,251−44.7% | Reduced | Holders |
| Q3 2025 | 2,609,353 | $56.3M | 1.7% | −132,223−4.8% | Reduced | Holders |
| Q2 2025 | 2,741,576 | $38.3M | 1.6% | +646,497+30.9% | Added | Holders |
| Q1 2025 | 2,095,079 | $28.2M | 1.3% | +275,000+15.1% | Added | Holders |
| Q4 2024 | 1,820,079 | $34.9M | 1.2% | −1,075,610−37.1% | Reduced | Holders |
| Q3 2024 | 2,895,689 | $65.9M | 2.3% | −6600.0% | Reduced | Holders |
| Q2 2024 | 2,896,349 | $37.7M | 1.4% | −2,135,071−42.4% | Reduced | Holders |
| Q1 2024 | 5,031,420 | $88.1M | 3.1% | +236,932+4.9% | Added | Holders |
| Q4 2023 | 4,794,488 | $104.4M | 4.9% | +1,112,741+30.2% | Added | Holders |
| Q3 2023 | 3,681,747 | $56.5M | 3.9% | +1,266,491+52.4% | Added | Holders |
| Q2 2023 | 2,415,256 | $57.5M | 4.6% | +329,558+15.8% | Added | Holders |
| Q1 2023 | 2,085,698 | $53.1M | 5.0% | +334,531+19.1% | Added | Holders |
| Q4 2022 | 1,751,167 | $51.2M | 6.0% | +114,956+7.0% | Added | Holders |
| Q3 2022 | 1,636,211 | $33.6M | 4.7% | +329,642+25.2% | Added | Holders |
| Q2 2022 | 1,306,569 | $15.1M | 3.0% | +50,518+4.0% | Added | Holders |
| Q1 2022 | 1,256,051 | $23.2M | 6.1% | +47,000+3.9% | Added | Holders |
| Q4 2021 | 1,209,051 | $23.9M | 6.8% | – | No prior filing | Holders |